Neuberg Diagnostics

Neuberg claims capability across more than 6,000 test varieties, far exceeding the roughly 1,000 offered by even the largest hospitals.

Leading position in newborn screening and reproductive genomics testing, per the company's own Kotak Alt funding announcement.

Company mission framed around personalised medicine made accessible regardless of income or geography.

Mass-market patients across income levels seeking accurate, affordable testing.

Oncology, reproductive medicine, inherited genetics, pharmacogenomics and nutrigenomics patients referred for specialised testing.

Patients book lab, radiology and genetic tests, plus home sample collection, directly through Neuberg's own mobile app rather than visiting a branch.

For home sample collections, the app lets patients track their phlebotomist's live location on a map, similar to a delivery-tracking experience.

Patients can view, download and share reports (with access to past test history) and manage bookings for multiple family members under a single account.

80% of labs are company-owned, the rest run as franchisees, organized in a hub-and-spoke structure.

Nationwide physical network as of the January 2025 Kotak Alt investment announcement.

Neuberg's network of owned and joint-venture labs (Anand Diagnostic, Supratech, Ehrlich, Pulse Diagnostics, Global Labs, Minerva Diagnostics) collectively runs more than 30 million diagnostic tests a year.

Chairman GSK Velu frames sourcing acquisitions, negotiating joint-venture structures, and integrating acquired labs onto the Neuberg platform as the company's core activity and growth engine.

Since its 2017 founding, Neuberg has grown at roughly double the diagnostics industry's rate through continuous lab and JV additions.

Chairman GSK Velu describes ongoing capital raises as fuel for additional acquisitions ahead of a planned stock market listing within two years.

First private lab in India to acquire the NovaSeq6000 sequencer; runs facilities in Ahmedabad, Chennai and Raleigh (NC, USA).

Accreditation underpins trust and ability to run complex/high-end tests.

Team of clinical pathologists, biochemists, geneticists and certified lab professionals.

Neuberg's core growth model: always take a majority stake in JVs with established regional players rather than build organically.

51% joint venture combining 10 Neuberg labs with Pulse Diagnostics' nine integrated diagnostic centres to cover Eastern/North Eastern India.

Joint venture combining Neuberg pathology with Star Imaging's radiology to build Maharashtra's largest integrated diagnostics network.

Kotak Strategic Situations India Fund II invested ₹940 crore to fund inorganic expansion ahead of a planned IPO.

Cricketer MS Dhoni endorses the Neuberg brand.

Core fee-for-test revenue across biochemistry, histopathology, radiology, cardiology and pathology investigations.

Higher-margin genomics testing for personalised medicine processed through the Neuberg Centre for Genomic Medicine.

Cumulative capital expenditure to date on network expansion (labs, collection centres, equipment), per chairman GSK Velu -- reflecting how capital-intensive physical network buildout is for the business.

Neuberg plans a further Rs 500 crore of capital expenditure over the next three years to keep expanding its lab and collection-centre network.

A single new integrated diagnostic centre in Chennai (CT, MRI, mammography, pathology and genomics under one roof) is being built on 60,000 sq ft at a cost of Rs 50 crore, illustrating the capex scale behind flagship facilities.